- Email: [email protected]
5286643 Rat osteosarcoma cell line OSR-8
573
PATENT ABSTRACTS mutation at least at a position which is, or corresponds with, position 479 and/or 482 of poliovirus type 3 Leon strain.
5286642 RAT OSTEOSARCOMA LINE OSR5TR2
CELL
Claus-Jens W Doersen, Robert J Isfort assigned to The Procter & Gamble Company The present invention relates to a novel cell line isolated from a rat osteosarcoma cell line has the following characteristics: a) a non-expressed p53 protein; b) a normal RB-I gene; c) a 10* amplified c-myc gene; d) a normal c-los gene; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL trademark growth pattern; g) tumorigenic in congenitally athymic mice; h) no alkaline phosphatase activity; i) an ability to produce one or more of the following growth factors: 1) an osteoblastic differentiation growth factor, 2) a non-heparin binding mitogenic growth factor, 3) a first heparin binding mitogenic growth factor, 4) a second heparin binding mitogenic growth factor, and 5) a third heparin binding mitogenic growth factor; and an ability to be serially propagated greater than sixty population doublings. The present invention also relates to growth factors having the characteristics of growth factors isolated from the rat osteosarcoma cell line. The present invention further relates to a process for producing such growth factors.
5286643 RAT OSTEOSARCOMA LINE OSR-8
heparin binding growth factor, 3) a second heparin binding growth factor, and 4) a third heparin binding growth factor; and j) an ability to be serially propagated greater than sixty population doublings. The present invention also relates to growth factors having the characteristics of growth factors isolated from the rat osteosarcoma cell line. The present invention further relates to a process for producing such growth factors comprising growing the cells of the present invention in a culture medium and recovering the growth factors.
5286644 RAT OSTEOSARCOMA LINE OSR-2
CELL
Claus-Jens W Doersen, Robert J Isfort assigned to The Procter & Gamble Company The present invention relates to a novel cell line isolated from a rat osteosarcoma having the following characteristics: a) a normal p53 gene as compared to a non-tumorigenic SpragueDawley rat cell control; b) a normal RB-1 gene as compared to a non-tumorigenic SpragueDawley rat cell control; c) a normal c-myc gene as compared to a non-tumorigenic SpragueDawley rat cell control; d) a normal c-fos gene as compared to a non-tumorigenic SpragueDawley rat cell control; e) a normal immediate early gene response following mitogenic stimulation; t) a canalicular Matrigel growth pattern; g) non-tumorigenic in congenitally athymic mice; h) high levels of alkaline phosphatase activity; i) a lack of autocrine growth factor production; and j) an ability to be serially propagated greater than sixty population doublings.
CELL
Claus-Jens W Doersen, Robert J Isfort assigned to The Procter & Gamble Company The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) a normal p53 gene; b) a normal RB-I gene; c) a normal cmyc gene; d) a normal c-fos gene; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL trademark growth pattern; g) poorly tumorigenic in congenitally athymic mice; h) no alkaline phosphatase activity; i) an ability to produce one or more of the following growth factors: 1) a non-heparin binding growth factor, 2) a first
5286645 RAT OSTEOSARCOMA LINE OSR3TRI
CELL
Claus-Jens W Doersen, Robert J Isfort assigned to The Procter & Gamble Company The present invention relates to a novel cell line isolated from a rat osteosarcoma having the following characteristics: A) a non-expressed p53 protein; B) a normal RB-I gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; C) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; D) a 50-fold amplified c-myc gene as com-
PATENT ABSTRACTS mutation at least at a position which is, or corresponds with, position 479 and/or 482 of poliovirus type 3 Leon strain.
5286642 RAT OSTEOSARCOMA LINE OSR5TR2
CELL
Claus-Jens W Doersen, Robert J Isfort assigned to The Procter & Gamble Company The present invention relates to a novel cell line isolated from a rat osteosarcoma cell line has the following characteristics: a) a non-expressed p53 protein; b) a normal RB-I gene; c) a 10* amplified c-myc gene; d) a normal c-los gene; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL trademark growth pattern; g) tumorigenic in congenitally athymic mice; h) no alkaline phosphatase activity; i) an ability to produce one or more of the following growth factors: 1) an osteoblastic differentiation growth factor, 2) a non-heparin binding mitogenic growth factor, 3) a first heparin binding mitogenic growth factor, 4) a second heparin binding mitogenic growth factor, and 5) a third heparin binding mitogenic growth factor; and an ability to be serially propagated greater than sixty population doublings. The present invention also relates to growth factors having the characteristics of growth factors isolated from the rat osteosarcoma cell line. The present invention further relates to a process for producing such growth factors.
5286643 RAT OSTEOSARCOMA LINE OSR-8
heparin binding growth factor, 3) a second heparin binding growth factor, and 4) a third heparin binding growth factor; and j) an ability to be serially propagated greater than sixty population doublings. The present invention also relates to growth factors having the characteristics of growth factors isolated from the rat osteosarcoma cell line. The present invention further relates to a process for producing such growth factors comprising growing the cells of the present invention in a culture medium and recovering the growth factors.
5286644 RAT OSTEOSARCOMA LINE OSR-2
CELL
Claus-Jens W Doersen, Robert J Isfort assigned to The Procter & Gamble Company The present invention relates to a novel cell line isolated from a rat osteosarcoma having the following characteristics: a) a normal p53 gene as compared to a non-tumorigenic SpragueDawley rat cell control; b) a normal RB-1 gene as compared to a non-tumorigenic SpragueDawley rat cell control; c) a normal c-myc gene as compared to a non-tumorigenic SpragueDawley rat cell control; d) a normal c-fos gene as compared to a non-tumorigenic SpragueDawley rat cell control; e) a normal immediate early gene response following mitogenic stimulation; t) a canalicular Matrigel growth pattern; g) non-tumorigenic in congenitally athymic mice; h) high levels of alkaline phosphatase activity; i) a lack of autocrine growth factor production; and j) an ability to be serially propagated greater than sixty population doublings.
CELL
Claus-Jens W Doersen, Robert J Isfort assigned to The Procter & Gamble Company The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) a normal p53 gene; b) a normal RB-I gene; c) a normal cmyc gene; d) a normal c-fos gene; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL trademark growth pattern; g) poorly tumorigenic in congenitally athymic mice; h) no alkaline phosphatase activity; i) an ability to produce one or more of the following growth factors: 1) a non-heparin binding growth factor, 2) a first
5286645 RAT OSTEOSARCOMA LINE OSR3TRI
CELL
Claus-Jens W Doersen, Robert J Isfort assigned to The Procter & Gamble Company The present invention relates to a novel cell line isolated from a rat osteosarcoma having the following characteristics: A) a non-expressed p53 protein; B) a normal RB-I gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; C) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; D) a 50-fold amplified c-myc gene as com-